30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Zimmer

$1,169MM, +6% (Americas $660MM, +8%; Europe $307MM, flat; Asia Pacific $202MM, +7%)

Reconstructive $868MM, +4% (Americas $476MM, +5%; Europe $240MM, flat; Asia Pacific $152MM, +7%)

  • Hips $338MM, +2% (Americas $157MM, +3%; Europe $113MM, -2%; Asia Pacific $68MM, +4%)
  • Knees $481MM, +5% (Americas $282MM, +5%; Europe 118MM, flat; Asia Pacific $81MM, +10%)
  • Extremities $49MM, +15%

Dental $61MM, -1%

Trauma $74MM, +3% (Americas +1%, Europe +6%, Asia Pacific +8%

Spine $54MM, +4%

Orthopaedic Surgical Products/Other $112MM, +28%


  • Acquired Knee Creations (Subchondroplasty joint preservation outpatient procedure) and NORMED Medizin Technik (extremities and trauma)
  • Hip sales supported by Continuum Acetabular Cup, Vivacit-E liners, ceramic heads
  • Encouraging U.S. traction for Avenir hip stem: compatible with anterior supine approach
  • Knee growth buoyed by Gel-One single injection hyaluronic acid sales
  • Trauma sales led by Trabecular Metal reverse shoulder, though competitive pressure slowed growth, particularly in the U.S.
  • Natural Nail and XtraFIx external fixation systems contributing to trauma growth
  • Excise tax impact $10 to $15 million of charges in quarter


Overall worldwide pricing -1.3%

  • Hip pricing -2.1%, positive volume/mix 3.8%
  • Knee pricing -1.4%, positive volume/mix 6.1%
  • Spine pricing stabilizing